Hormone Replacement Therapy (HRT) – (pending) $772 million set aside so far
Written by Andrew Sarski on June 8, 2012
Wyeth Pharmaceuticals, a subsidiary of Pfizer, is facing a class action lawsuit filed on behalf of women who used the company’s hormone replacement therapy (HRT) and subsequently developed breast cancer. According to the suit, Wyeth allegedly failed to warn patients using the firm’s Premplus and Premarin therapies about studies that showed a connection between HRT and breast cancer. Wyeth has reportedly set aside $772 million to resolve HRT personal injury claims.